Crossmark

Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers

Crossref DOI link: https://doi.org/10.1016/j.medcli.2021.09.013

Published Print: 2022-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martínez-Gallo, Mónica http://orcid.org/0000-0003-3222-2380
Esperalba, Juliana

Pujol-Borrell, Ricardo

Sandá, Víctor

Arrese-Muñoz, Iria

Fernández-Naval, Candela

Antón, Andrés

Cardona, Victoria

Labrador-Horrillo, Moisés

Pumarola, Tomás

Hernandéz-González, Manuel
Funding

Funding for this research was provided by:

European Regional Development Fund

Instituto de Salud Carlos III (COV20/00416)
License Information

Text and Data Mining valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01

stm-asf valid from 2022-08-01
More Information

This article is maintained by: Elsevier

Article Title: Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2021.09.013

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.